MedTrace Logo

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

NCT00287846 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-08-30

No results posted yet for this study

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I/II trial is studying the side effects of imatinib mesylate and to see how well it works in treating patients with recurrent or refractory aggressive fibromatosis.

Conditions

  • Desmoid Tumor

Interventions

DRUG

imatinib mesylate

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Jean-Yves Blay, MD, PhD · Hopital Edouard Herriot - Lyon

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-02-28
Completion
2010-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00287846 on ClinicalTrials.gov